HPMA copolymer platinates as novel antitumour agents: in vitro properties, pharmacokinetics and antitumour activity in vivo.
暂无分享,去创建一个
R. Duncan | E. Gianasi | E. Evagorou | M. Wasil | A. Keddle | G. Wilson | R Duncan | E G Evagorou | E Gianasi | M Wasil | A Keddle | G Wilson | Ruth Duncan
[1] M. Wilchek,et al. Soluble polymers as carriers of cis-platinum , 1989 .
[2] J. Kopeček,et al. Degradation of side-chains ofN-(2-hydroxypropyl)methacrylamide copolymers by lysosomal thiol-proteinases , 1982, Bioscience reports.
[3] L. Murray,et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[4] L. Kèlland,et al. New platinum antitumor complexes. , 1993, Critical reviews in oncology/hematology.
[5] J. Foekens,et al. Prognostic significance of cathepsins B and L in primary human breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] A. Eastman,et al. Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells. , 1987, Cancer research.
[7] Teruo Okano,et al. Introduction of cisplatin into polymeric micelle , 1996 .
[8] K. Ulbrich,et al. Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. , 1994, British Journal of Cancer.
[9] T. A. Connors. Is there a future for cancer chemotherapy? The Michel Clavel Lecture. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] K. Ulbrich,et al. The pharmacokinetics of polymer-bound adriamycin. , 1990, Biochemical pharmacology.
[11] V. Devita,et al. Cancer : Principles and Practice of Oncology , 1982 .
[12] B. Chabner,et al. Cancer Chemotherapy: Principles and Practice , 1990 .
[13] C. Sorenson,et al. Mechanisms of Resistance to Platinum Drugs , 1988 .
[14] J. Trosko,et al. Platinum Compounds: a New Class of Potent Antitumour Agents , 1969, Nature.
[15] E. Neuse,et al. cis-Diaminedichloroplatinum(II) complexes reversibly bound to water-soluble polyaspartamide carriers for chemotherapeutic applications. II: Platinum coordination to ethylenediamine ligands attached to poly(ethylene oxide)-grafted carrier polymers , 1995 .
[16] I. Pastan,et al. Characterisation of high-level cisplatin-resistant cell lines established from a human hepatoma cell line and human KB adenocarcinoma cells: cross-resistance and protein changes. , 1995, British Journal of Cancer.
[17] S. Kaye,et al. Activity of N-(2-hydroxypropyl)methacrylamide copolymers containing daunomycin against a rat tumour model. , 1989, Biochemical pharmacology.
[18] R. Duncan,et al. Drug-polymer conjugates: potential for improved chemotherapy. , 1992, Anti-cancer drugs.
[19] D. Sgouras,et al. Methods for the evaluation of biocompatibility of soluble synthetic polymers which have potential for biomedical use: 1 — Use of the tetrazolium-based colorimetric assay (MTT) as a preliminary screen for evaluation ofin vitro cytotoxicity , 1990 .
[20] L. Kèlland,et al. Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes. , 1992, British Journal of Cancer.
[21] M. Wilchek,et al. Cis-platinum (II) complexes of carboxymethyl-dextran as potential antitumor agents. II. In vitro and in vivo activity. , 1986, Cancer biochemistry biophysics.
[22] H. Maeda,et al. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.
[23] T. Imai,et al. Alteration of pharmacokinetics and nephrotoxicity of cisplatin by alginates. , 1997, Journal of pharmaceutical sciences.
[24] K. Ulbrich,et al. Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. 3. Evaluation of adriamycin conjugates against mouse leukaemia L1210 in vivo , 1989 .
[25] S. Hollander,et al. Review of platinum anticancer compounds. , 1993, Journal of medicine.
[26] K. Ulbrich,et al. Biocompatibility of N-(2-hydroxypropyl) methacrylamide copolymers containing adriamycin. Immunogenicity, and effect on haematopoietic stem cells in bone marrow in vivo and mouse splenocytes and human peripheral blood lymphocytes in vitro. , 1989, Biomaterials.
[27] A. W. Prestayko,et al. Cisplatin (cis-diamminedichloroplatinum II). , 1979, Cancer treatment reviews.
[28] M. Wilchek,et al. Increased therapeutic efficacy of CIS‐platinum complexes of poly‐L‐glutamic acid against a murine carcinoma , 1987, International journal of cancer.
[29] M. Wilchek,et al. Cis-platinum(II) complexes of carboxymethyl-dextran as potential antitumor agents. I. Preparation and characterization. , 1986, Cancer biochemistry biophysics.
[30] K. Ulbrich,et al. Macromolecular prodrugs for use in targeted cancer chemotherapy: melphalan covalently coupled to N- (2-hydroxypropyl) methacrylamide copolymers , 1991 .
[31] D. V. Von Hoff,et al. Cis-diamminedichloroplatinum (II). A new anticancer drug. , 1977, Annals of internal medicine.
[32] Stephen B. Howell. Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy , 1991, Springer US.